What is Zacks Research's Forecast for CORT Q4 Earnings?

Key Points

• Analysts at Zacks Research have raised their Q4 2026 earnings per share estimate for Corcept Therapeutics to $0.55, an increase from the previous estimate of $0.53.
• Corcept Therapeutics recently reported a quarterly EPS of $0.17, aligning with consensus expectations, but its revenue fell short of estimates.
• Institutional investors own 93.61% of Corcept Therapeutics, indicating strong interest from hedge funds and institutional investors in the company's stock.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at Zacks Research increased their Q4 2026 EPS estimates for Corcept Therapeutics in a research note issued to investors on Wednesday, July 30th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $0.55 for the quarter, up from their previous estimate of $0.53. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q1 2027 earnings at $0.68 EPS, Q2 2027 earnings at $0.94 EPS and FY2027 earnings at $4.13 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Thursday, July 31st. The biotechnology company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.23 by $0.06. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 19.86%. The firm had revenue of $194.43 million for the quarter, compared to the consensus estimate of $199.40 million. During the same period in the previous year, the firm posted $0.32 EPS. The business's quarterly revenue was up 18.7% on a year-over-year basis.

Several other research firms have also recently issued reports on CORT. Piper Sandler lowered their price objective on shares of Corcept Therapeutics from $131.00 to $121.00 and set an "overweight" rating for the company in a research report on Friday. HC Wainwright lowered their price target on shares of Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Truist Financial set a $135.00 price target on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. Wall Street Zen cut shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Finally, Canaccord Genuity Group lowered their price target on shares of Corcept Therapeutics from $142.00 to $137.00 and set a "buy" rating for the company in a research report on Friday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $134.50.

Corcept Therapeutics Stock Performance

Corcept Therapeutics stock traded up $1.83 during trading hours on Thursday, hitting $69.00. The company had a trading volume of 2,107,375 shares, compared to its average volume of 832,519. The firm has a market cap of $7.32 billion, a P/E ratio of 61.06 and a beta of 0.20. Corcept Therapeutics has a 1 year low of $32.33 and a 1 year high of $117.33. The company has a 50-day moving average price of $71.62 and a two-hundred day moving average price of $68.33.

Insider Transactions at Corcept Therapeutics

In other news, Director David L. Mahoney sold 27,352 shares of the firm's stock in a transaction dated Friday, May 16th. The shares were sold at an average price of $74.23, for a total value of $2,030,338.96. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider William Guyer sold 32,262 shares of Corcept Therapeutics stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $74.17, for a total transaction of $2,392,872.54. Following the transaction, the insider directly owned 5,487 shares in the company, valued at $406,970.79. This trade represents a 85.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 173,038 shares of company stock valued at $13,237,621. Company insiders own 20.80% of the company's stock.

Institutional Investors Weigh In On Corcept Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Focus Partners Wealth boosted its holdings in shares of Corcept Therapeutics by 0.5% in the 1st quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company's stock valued at $3,797,000 after buying an additional 170 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Corcept Therapeutics by 1.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company's stock valued at $730,000 after purchasing an additional 180 shares in the last quarter. Brooklyn Investment Group increased its holdings in shares of Corcept Therapeutics by 99.5% in the 1st quarter. Brooklyn Investment Group now owns 373 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 186 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Corcept Therapeutics by 0.5% in the 2nd quarter. Louisiana State Employees Retirement System now owns 44,100 shares of the biotechnology company's stock valued at $3,237,000 after purchasing an additional 200 shares in the last quarter. Finally, Concurrent Investment Advisors LLC increased its holdings in shares of Corcept Therapeutics by 3.4% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 6,175 shares of the biotechnology company's stock valued at $453,000 after purchasing an additional 205 shares in the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.